Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: How much data do we need?

Journal of Clinical Oncology

Volumn 22, Issue 15, 2004, Pages 2978-2981

  Crane, Christopher H ^a   Sargent, Daniel J ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; UFT; AMINOACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; FLUOROQUINACRINE;

ACUTE TOXICITY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; METASTASIS; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; NOTE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RECTUM TUMOR;

ADMINISTRATION, ORAL; AMINOACRIDINES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS;

EID: 4143143285     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.953     Document Type: Editorial

References (24)

1. Fernandez-Martos C, Aparicio J, Bosch C, et al: Phase II multicenter study of pre-operative oral uracil and tegafur (UFT) and concomitant radiotherapy in operable rectal cancer: Final results with 3 years of follow-up. J Clin Oncol 22:3016-3022, 2004
2. O'Connell MJ, Martenson JA, Wieand HS. et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994
3. Smalley S, Benedetti J, Williamson S, et al: Intergroup 0144-phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer: Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole before and after XRT + bolus 5-FU + LV. Proc Am Soc Clin Oncol 22:251, 2003 (abstr 1006)
4. Tepper JE, O'Connell MJ, Petroni GR, et al: Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114. J Clin Oncol 15:2030-2039, 1997
5. Dunst J, Reese T, Sutter T, et al: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:3983-3991, 2002
6. Crane CH, Skibber JM, Feig BW, et al: Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97:517-524, 2003
7. Grann A, Feng C, Wong D, et al: Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 49:987-995, 2001
8. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001
9. Sauer R: German Rectal Cancer Group: Adjuvant versus neoadjuvant combined modality treatment for locally advanced rectal cancer: First results of the German Rectal Cancer Study (CAO/ARO/AIO-94). Int J Radiat Oncol Biol Phys 57:5124-3125, 2003 (suppl 2)
10. Minsky BD, Coia L, Haller DG, et al: Radiation therapy for rectosigmoid and rectal cancer: Results of the 1992-1994 Patterns of Care process survey. J Clin Oncol 16:2542-2547, 1998
11. Coia LR, Gunderson LL, Haller D, et al: Outcomes of patients receiving radiation for carcinoma of the rectum. Results of the 1988-1989 patterns of care study. Cancer 86:1952-1958, 1999
12. Kozin SV, Boucher Y, Hicklin DJ, et al: Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61:39-44, 2001
13. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000
14. Kirichenko AV, Rich TA: Radiation enhancement by 9-aminocamptothecin: The effect of fractionation and timing of administration. Int J Radiat Oncol Biol Phys 44:659-664, 1999
15. Blackstock AW, Tepper J, Hess S: Oxaliplatin: In vitro and in vivo evidence of radiation sensitizing activity. Int J Radiat Oncol Biol Phys 46:724, 2000 (abstr 92)
16. Rosenthal D, Catalano P, Haller D, et al: A phase I study of preoperative radiation therapy with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal adenocarcinoma. Proc Am Soc Clin Oncol 22:273, 2003 (abstr 1094)
17. Crane CH, Ellis L, Xiong H, et al: Preliminary results of a phase I study of rhuMab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP). ASCO GI Symposium, San Francisco, CA, January 2004 (abstr 85)
18. De Gramont A, Banzi M, Navarro M, et al: Oxaliplatin/5-Fu/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc Am Soc Clin Oncol 22:253, 2003 (abstr 1015)
19. Gunderson LL, Sargent DJ, Tepper JE, et al: Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis. J Clin Oncol 22:1785-1796, 2004
20. Anonymous: Improved survival with preoperative radiotherapy in resectable rectal cancer: Swedish Rectal Cancer Trial. N Engl J Med 336:980-987, 1997
21. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
22. Grothey A, Jordan K, Keller O, et al: Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy of advanced colorectal cancer. Proc Am Soc Clin Oncol 22:255, 2003 (abstr 1022)
23. Van Cutsem E, Twelves C, Tabernero J, et al: XELOX: Mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective 1st line option for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:255, 2003 (abstr 1023)
24. Twelves C, Wong A, Nowacki M, et al: Improved safety results of a phase III trial of capecitabine vs bolus 5-FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study). Proc Am Soc Clin Oncol 22:294, 2003 (abstr 1182)